Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Surging Prevalence of Genetic Diseases
4.2.2 Growing Investments in Healthcare Sector
4.2.3 Rapid Shift of the Pharmaceutical Industry Toward Innovative Biologics
4.3 Market Restraints
4.3.1 High Cost of Nucleic Acid Research
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value in USD million)
5.1 By Product Type
5.1.1 RNA interference [RNAi] and short interfering RNAs [siRNAs]
5.1.2 Antisense Oligonucleotides (ASOs)
5.1.3 Other Product Types
5.2 By Application
5.2.1 Autoimmune Disorders
5.2.2 Infectious Diseases
5.2.3 Genetic Disorders
5.2.4 Cancer
5.2.5 Other Applications
5.3 By End User
5.3.1 Hospitals and Clinics
5.3.2 Academic and Research Institutes
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Silence Therapeutics PLC
6.1.2 Ionis Pharmaceuticals Inc.
6.1.3 Novartis Pharma AG
6.1.4 Arrowhead Pharmaceuticals Inc.
6.1.5 Stoke Therapeutics Inc.
6.1.6 Moderna Inc.
6.1.7 Alnylam Pharmaceuticals Inc.
6.1.8 Biogen Inc.
6.1.9 Wave Life Sciences
6.1.10 Sarepta Therapeutics Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS